Selected Quarterly Financial Information

12 Months Ended

Dec. 31, 2017

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Financial Information (Unaudited)

SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)

(in thousands, except per share data)

	First			Second			Third			Fourth
	Quarter			Quarter			Quarter			Quarter
REVENUE:
2017	$	45,059		$	47,818		$	43,999		$	52,826	*
2016		43,016	**		47,083	**		45,252	**		45,029	**
2015		33,831			35,526			36,703			39,838
GROSS MARGIN:
2017	$	29,512		$	32,905		$	29,862		$	36,363	*
2016		27,621	**		30,301	**		29,782	**		31,195	**
2015		19,667			21,554			22,982			26,516
NET INCOME (LOSS):
2017	$	2,223		$	3,163		$	1,325		$	(3,007)	*
2016		2,541	**		2,347	**		2,993	**		2,897	**
2015		(274)			(502)			2,145			2,636
INCOME (LOSS) PER COMMON SHARE—DILUTED:
2017	$	0.06		$	0.09		$	0.04		$	(0.09)	*
2016		0.08	**		0.07	**		0.09	**		0.09	**
2015		(0.01)			(0.02)			0.07			0.09

*In December 2017 we completed our acquisition of JOTEC, which is also being operated as a wholly owned subsidiary of CryoLife.

**In January 2016 we completed our acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly owned subsidiary of CryoLife.  In 2016 we also sold our HeRO Graft product line and our ProCol product line, and ceased sales of these products during 2016.